ST Hulubao (605199.SH) released its 2026 interim report, swinging from profit to loss, with net profit attributable to the parent company at negative 113 million yuan, a decrease of 116 million yuan compared with the same period last year, down 4805.36% year-on-year. Total operating revenue was 241 million yuan, down 52.55% year-on-year. Net cash inflow from operating activities was 44.4934 million yuan. The company's asset-liability ratio rose to 85.71%, gross margin fell to 16.44%, ROE was negative 37.91%, and diluted earnings per share was negative 0.28 yuan.
Hainan Huluwa Pharmaceutical Group Co LtdCompany swung to a net loss of 113 million yuan in its 2026 interim report, with revenue down 52.55% and margins deteriorating.
